| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 7,727 | -46 |
| Net change in cash, cash equivalents and restricted cash | 3,310 | 22,658 |
| Cash and cash equivalents at beginning of period | 58,942 | - |
| Cash and cash equivalents at end of period | 62,252 | - |
C4 Therapeutics, Inc. (CCCC)
C4 Therapeutics, Inc. (CCCC)